In this week’s edition of InnovationRx, we look at Trump's drug pricing executive order, how the cofounder of Hims became a ...

The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Novo Nordisk has entered a deal with Septerna for oral metabolic ... particularly with Eli Lilly’s rival GLP-1/GIP dual ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...